NASDAQ:NBIX - Neurocrine Biosciences Stock Price, Forecast & News

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Tuesday, February, 4th. The company reported $0.35 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.75 by $0.40. The business had revenue of $244.10 million for the quarter, compared to the consensus estimate of $231.54 million. Neurocrine Biosciences had a return on equity of 8.27% and a net margin of 4.70%. The company's quarterly revenue was up 85.8% on a year-over-year basis. During the same period last year, the firm earned $0.19 earnings per share. View Neurocrine Biosciences' Earnings History.

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, May 4th 2020. View Earnings Estimates for Neurocrine Biosciences.

14 analysts have issued 12-month price targets for Neurocrine Biosciences' shares. Their forecasts range from $88.00 to $153.00. On average, they anticipate Neurocrine Biosciences' stock price to reach $117.00 in the next year. This suggests a possible upside of 12.3% from the stock's current price. View Analyst Price Targets for Neurocrine Biosciences.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurocrine Biosciences.

News stories about NBIX stock have been trending neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurocrine Biosciences earned a news impact score of 0.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Neurocrine Biosciences.

Neurocrine Biosciences saw a decline in short interest during the month of January. As of January 15th, there was short interest totalling 4,240,000 shares, a decline of 8.4% from the December 31st total of 4,630,000 shares. Based on an average daily trading volume, of 936,000 shares, the short-interest ratio is currently 4.5 days. Currently, 4.7% of the shares of the company are sold short. View Neurocrine Biosciences' Current Options Chain.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Exelixis (EXEL), Twilio (TWLO), Illumina (ILMN) and Sarepta Therapeutics (SRPT).

Neurocrine Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (7.99%), Capital International Investors (6.32%), Perceptive Advisors LLC (3.91%), Perceptive Advisors LLC (3.91%), Alliancebernstein L.P. (1.34%) and Pictet Asset Management Ltd. (0.93%). Company insiders that own Neurocrine Biosciences stock include Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View Institutional Ownership Trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Janus Henderson Group PLC, Perceptive Advisors LLC, Perceptive Advisors LLC, Russell Investments Group Ltd., Pictet Asset Management Ltd., Marshall Wace North America L.P. and First Trust Advisors LP. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith and Matt Abernethy. View Insider Buying and Selling for Neurocrine Biosciences.

NBIX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Sumitomo Mitsui Trust Holdings Inc., Victory Capital Management Inc., Victory Capital Management Inc., Parkman Healthcare Partners LLC, Swiss National Bank, Cubist Systematic Strategies LLC and AXA. View Insider Buying and Selling for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $104.20.

Neurocrine Biosciences has a market capitalization of $9.62 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.View Additional Information About Neurocrine Biosciences.

The official website for Neurocrine Biosciences is http://www.neurocrine.com/.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]